tbuckley/cabot-search huggingface dataset:
Occult hepatitis B and occult hepatitis C viremia in patients with hematologic malignancies.
Authors: Harrys A. Torres, Parag Mahale, Dimitrios P Kontoyiannis, F. Blaine F. Blaine Hollinger
Journal: Journal of Clinical Oncology (2012)

e17016 Background: Occult Hepatitis B (OHB)and Hepatitis C (OHC) in patients with hematological malignancies (HM) are understudied, mainly because biopsies to identify these viruses in the liver are often not performed due to an associated risk of complications (e.g., bleeding). We describe our retrospective experience of patients with HM tested for OHB and OHC. Methods: Between 09/09 and 11/10, 18 unselected consecutive patients with an abnormal liver panel were tested for both OHB and OHC which was defined as detectable viremia in the absence of HBsAg and anti-HCV, respectively. Severe liver dysfunction was defined as ALT &gt;10 times the upper limit of normal (&gt;560 IU/L) and/or a total bilirubin &gt;6 mg/dL. Plasma samples were tested for HBV DNA and HCV RNA by using real-time PCR (Cobas Taqman HBV and HCV Tests-Roche Molecular Systems). Results: Most patients (12 or 67%) had leukemia, followed by lymphoma (5 patients or 28%). Two patients (11%) had OHB, and none had OHC.The 2 patients with OHB were born in areas with an intermediate to high prevalence of HBV; both had only low grade viremia (&lt;29 IU/mL). At the time HBV DNA testing was performed, peak ALT levels in these 2 patients were 843 IU/L and 6,047 IU/L compared to a median peak ALT of 302 IU/L (range, 84-1,320 IU/L) among those without OHB (P=0.03). Severe liver dysfunction occurred in the 2 (100%) patients with OHB compared to 6 (38%) of the non-OHB cases (P=0.1). Durations of ALT elevation were 12 and 17 days in patients with OHB, compared to a median duration of 13 days (range, 5-73 days) in non-OHB patients. Co-infections were identified in 1 patient with OHB and in 10 (63%) without OHB. The 2 patients with OHB and 8 (50%) patients without OHB died within 6 months after HBV DNA testing. Conclusions: Although our data are limited, in a group of cancer patients in whom a liver biopsy is not available, detection of HBV DNA or HCV RNA in serum in the absence of HBsAg or anti-HCV identifies a subset of patients with occult viral hepatitis, a phenomenon of unclear clinical significance.
Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983
Authors: T. Gruenberger, H. Sorbye, M. Debois, U. Bethe, J. Primrose, P. Rougier, D. Jaeck, M. Finch-Jones, E. Van Cutsem, B. Nordlinger
Journal: Journal of Clinical Oncology (2006)

3500 Background: After resection of LM, 5y survival is 30%, but cancer recurrence is frequent. The benefit of combining surgery and CT has not yet formally been proven. Methods: This study evaluates the value of pre- and postoperative CT in patients with potentially resectable liver metastases from colorectal cancer. Between September 2000 and July 2004, 364 patients were randomized between peri-operative FOLFOX4 (oxaliplatin 85mg/m 2 and LV5FU2), 6 cycles before and 6 cycles after surgery (182 patients), and surgery alone (182 patients). The primary endpoint was progression free survival. The purpose of this analysis was to evaluate tumor response to pre-operative treatment and determine if CT induces a tumor size reduction. Results: Baseline characteristics were similar in both arms: median age: 62.5 yrs, prior adjuvant CT: 41.8%, 1 to 3 metastases: 92.3%, T3 or T4: 80.8%. In the CT arm, 97.7% of the patients were documented to have completed pre-operative CT (81.5% received 6 preoperative cycles). 28.9% of the patients who started pre-operative CT required a dose reduction. Of all patients entered in the trial, 88.3% and 94.9% underwent surgery in the CT and surgery arms, respectively. Resection was achieved in 95.6% of the patients operated (84.4% of all patients) in the CT arm, and 89.2% of the patients operated (84.7% of all patients) in the surgery arm. As previously reported, preoperative chemotherapy was safely administered. From imaging data (CT scan), median sum of largest diameters of lesions was 45 mm [Q1-Q3:28.0–70.0] (both arms) before treatment and decreased to 30 mm [Q1-Q3: 15.0–55.0] after CT (median relative difference of 29.7%). At pathological examination, median sum of largest diameters of lesions was 34.5 mm [Q1-Q3:20.0–53.0] in the CT arm and 45 mm [Q1-Q3: 29.0–69.0] in the surgery arm. Conclusions: CT scan measurements were consistent with those performed at pathological examination. Pre-operative CT with 6 cycles of FOLFOX4 resulted in a decrease in diameter of lesions. Since size of metastases at time of surgery is known to have an impact on survival, it is possible that preoperative chemotherapy will improve survival. Survival data should be available at the end of 2006. No significant financial relationships to disclose.
CORONARY ARTERY CALCIUM SCORE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH MILD TO MODERATE CHRONIC KIDNEY DISEASE INSIGHTS FROM CLARIFY
Authors: Nour Tashtish, Sadeer Al-Kindi, Mirela Dobre, Imran Rashid, Jared Durieux, Scott Billings, Robert C. Gilkeson, Sanjay Rajagopalan
Journal: Journal of the American College of Cardiology (2020)
Abstract 115: One-Year Outcomes in Individual Domains of the Cerebral Performance Category Extended
Authors: Katharyn L Flickinger, Melissa J Repine, Stephany Jaramillo, Allison C Koller, Margo Holm, Elizabeth Skidmore, Clifton W Callaway, Jon C Rittenberger
Journal: Circulation (2018)

Introduction: Cognitive and physical impairments are common in cardiac arrest survivors. Global measures including the Modified Rankin Scale (mRS), Cerebral Performance Category (CPC) and the 10-domain CPC-Extended (CPC-E) tend to improve over 1 year. The CPC-E is scored from 1-5 with higher scores signifying greater impairment. However, with the CPC-E, individual functional domains (alertness, logical thinking, attention, motor skills, short-term memory, basic and complex activities of daily living (ADL), mood, fatigue, and return to work) may recover at different rates. Hypothesis: We hypothesized that patients would have recovery in all domains of the CPC-E at 1 year after index cardiac arrest. Methods: A prospective cohort study of cardiac arrest survivors was conducted between 2/1/16 and 5/31/17. Chart review was done for baseline demographic data. Outcome measures including mRS, CPC, and CPC-E scores were assessed at discharge, 3 months, 6 months, and 1 year. We defined recovery of a CPC-E domain when &gt;90% of patients had scores of 1-2 in that domain. Results: Of 71 subjects, 35 completed the CPC-E at discharge, 35 at 3 months, 25 at 6 months and 31 at 1 year. The most common reasons for exclusion were patient declined or were lost to follow up. The majority (N=37; 52%) were female, with a mean (SD) age of 58(17) years. Most arrests occurred out of hospital (N= 49; 69%), 27 (38%) had a shockable rhythm and the majority (N=37; 54%) were discharged home. CPC-E domains of alertness (N=35, 100%) logical thinking (N=35; 100%), and attention (N=33; 94%) recovered by hospital discharge. BADLs were recovered by 3 months (N=33; 94%). The majority of patients (N=24;77%) experienced slight-to-no disability or symptoms (mRS 0-2 / CPC 1-2) at 1 year follow up. CPC-E short term memory (67%), motor (87%), mood (87%), fatigue (13%), complex ADL (74%), and return to work (55%) did not recover fully by 1 year. Conclusions: In survivors of cardiac arrest, CPC-E domains of alertness, logical thinking, and attention recover rapidly, while domains of short term memory, motor, mood, fatigue, complex ADL and ability to return to work are chronically impaired 1 year after arrest. Interventions to improve recovery in these domains are needed.
Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix.
Authors: Yutaka Nagai, Takafumi Toita, Morihiko Inamine, Wataru Kudaka, Tomoko Nakamoto, Akihiko Wakayama, Takuma Ooyama, Akemi Tokura, Yoichi Aoki
Journal: Journal of Clinical Oncology (2012)

5086 Background: Adenocarcinoma of the cervix has a worse prognosis than its squamous counterpart, particularly when cancer cells spread beyond the uterine cervix. This is derived from the observation that adenocarcinoma is less sensitive to radiotherapy (RT) and chemotherapy It is unclear whether cisplatin-based concurrent chemoradiotherapy (CCRT) has the same effect on adenocarcinoma as on squamous cell carcinoma. Methods: We retrospectively analyzed 32 patients with stage IIB–IVA cervical adenocarcinoma who were treated with RT or CCRT. Fourteen patients were treated with RT from 1983–1996, 8 with CCRT using cisplatin alone (CCRT-P) from 1997–2002, and 10 with CCRT using cisplatin+paclitaxel (CCRT-TP) after 2003. The patients were treated with external beam radiotherapy, and low-dose or high-dose rate intracavitary brachytherapy. For CCRT-P, the patients received 20 mg/m 2 cisplatin for 5 days every 3 weeks, and for CCRT-TP, the patients received 50 mg/m 2 cisplatin every 3 weeks and 50 mg/ m 2 paclitaxel weekly. Results: A complete response was achieved in 7/14 patients in the RT, 4/8 patients in the CCRT-P, and 9/10 patients in the CCRT-TP group. Ten of the 14 patients in the RT, 7/8 patients in the CCRT-P, and 2/10 patients in the CCRT-TP group experienced locoregional recurrence. The 5-year overall survival rate in the RT, CCRT-P, and CCRT-TP groups was 7.1%, 25.0%, and 74.1%, respectively (p = 0.0094), and their central disease-free survival rate was 21.4%, 12.5%, and 78.8%, respectively (p=0.0119). The acute toxicities associated with CCRT-TP are manageable. Regarding late toxicity of CCRT-TP, no grade 3/4 adverse effect was observed. Conclusions: The present study demonstrated that CCRT-TP achieved much better local control for adenocarcinoma of the cervix, leading to a decrease in locoregional recurrence. Prospective trials in larger series of patients are urgently needed.
Variation in health-related quality of life (HRQoL) during chemotherapy for advanced non-small cell lung cancer.
Authors: Bjørn Henning Grønberg, Sveinung Sørhaug, Harald Harris Hjelde, Guro Birgitte Stene, Tore Amundsen
Journal: Journal of Clinical Oncology (2013)

9562 Background: Physicians might overestimate benefits and underestimate toxicity of cancer therapy. Thus, patient reported HRQoL is an important part of evaluating treatment effect and assessing side effects. HRQoL is commonly reported once per chemotherapy cycle and just prior to administration of the next course (day 0). Several studies have not detected differences in HRQoL despite differences in physician-observed toxicity. We hypothesized that HRQoL varies during chemotherapy cycles; that side effects are most pronounced the first week after chemotherapy administration; and that repeated assessments improve the ability to detect differences in HRQoL. Methods: Patients were randomized to receive 3 courses of either vinorelbine/carboplatin (VC) or gemcitabine/carboplatin (GC) every 3 weeks. They reported HRQoL on the EORTC QLQ C30 + LC13 on day 0, 3, 8, 11, 15 and 22 of each cycle. A difference in mean scores of &gt; 5 points is considered clinically detectable. Results: 52 pts (VC: 25, GC: 27); median age 65; 56 % men; 85 % stage IV; 93 % performance status 0-1; 75 % completed 3 cycles; 32 % response-rate; 71 % grade 3-4 toxicity. Baseline characteristics; treatment administered and outcomes of therapy were similar between treatment arms. Completion rates of QLQs were 96-64 %. There were significant variations in mean scores during cycles for several domains (mean scores during cycle 1 for some domains are listed in the table). For several domains, there were differences of &gt; 5 points between the treatments arms at day 3-15 that were not detectable on day 22 (day 0 of next cycle). In general, treatment related symptoms were most pronounced on day 3 in every cycle. Conclusions: Our results suggest that timing and number of assessments influence the likelihood of detecting differences in HRQoL during chemotherapy. Day 3 was the best time point for assessing reduced function and side effects of the regimens administered in our trial. [Table: see text]
EFFECT OF THE DIETARY APPROACHES TO STOP HYPERTENSION (DASH) DIET ON BLOOD PRESSURE IN ADULTS WITH AND WITHOUT HYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Konstantinos P. Tsioufis, Christina Filippou, Costas Thomopoulos, Costas Mihas, Kyriakos Dimitriadis, Lida Sotiropoulou, Christina Chrysochoou, Petros Nihoyannopoulos, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2020)
MECHANICAL CAUSE OF EARLY OCCLUSION AFTER SUCCESSFUL PERCUTANEOUS CORONARY INTERVENTION EVALUATED BY IVUS
Authors: Ge Jin, Gary Mintz, Khady Fall, Ziad Ali, Ajay Kirtane, Tamim Nazif, Leroy Rabbani, Philip Green, Manish Parikh, Michael Collins, Dimitrios Karmpaliotis, Jeffrey Moses, Akiko Maehara
Journal: Journal of the American College of Cardiology (2020)
Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy
Authors: Wen-Yen Huang, Chiao-Ling Tsai, Jenny Y. Que, Cheng-Hsiang Lo, Yu-Ju Lin, Yang-Hong Dai, Jen-Fu Yang, Po-Chien Shen, Mei-Hsuan Lee, Jason Chia-Hsien Cheng
Journal: Liver Cancer (2020)

Stereotactic body radiotherapy (SBRT) is an emerging treatment modality for hepatocellular carcinoma (HCC) with promising outcome. However, appropriate survival prediction models are scarce. This study aimed to develop a simple and clinically useful prognostic nomogram for patients with nondistant metastatic Barcelona Clinic Liver Cancer (BCLC) stage C HCC undergoing SBRT.The data were based on a prospective multi-institutional registry enrolling 246 patients with nondistant metastatic BCLC stage C HCC treated with SBRT between January 1, 2008 and December 31, 2016. They were randomly divided into two subsets: 164 into the development cohort and 82 into the validation cohort. We identified and included prognostic factors for survival to derive a nomogram in the development cohort. The predictability of the nomogram was evaluated in the validation cohort. The area under the receiver operating characteristic curve (AUROC) and the calibration plot were used to evaluate the performance of the nomogram.The median survival was 13.5 months, with 1- and 2-year overall survival (OS) rates of 55.0 and 32.9%, respectively. Number of tumors, largest tumor size, macrovascular invasion, Child-Turcotte-Pugh class, and biologically effective dose were significantly associated with OS (p < 0.05). These predictors were included to develop a nomogram with an AUROC of 0.77 (0.73-0.87). The prediction model was well calibrated in the validation cohort. The OS for patients who were divided by their risk scores differed significantly (p < 0.001).The nomogram we generated had discriminatory and satisfactory predictability for OS among nonmetastatic BCLC stage C HCC patients treated with SBRT. It demands further validations with cross-country data to confirm its worldwide usefulness.
Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma
Authors: Nathiya Muthalagu, Tiziana Monteverde, Ximena Raffo-Iraolagoitia, Robert Wiesheu, Declan Whyte, Ann Hedley, Sarah Laing, Björn Kruspig, Rosanna Upstill-Goddard, Robin Shaw, Sarah Neidler, Curtis Rink, Saadia A. Karim, Katarina Gyuraszova, Colin Nixon, William Clark, Andrew V. Biankin, Leo M. Carlin, Seth B. Coffelt, Owen J. Sansom, Jennifer P. Morton, Daniel J. Murphy
Journal: Cancer Discovery (2020)

Abstract MYC is implicated in the development and progression of pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumor development has been difficult to define. We used modestly elevated expression of human MYC, driven from the Rosa26 locus, to investigate the pancreatic phenotypes arising in mice from an approximation of MYC trisomy. We show that this level of MYC alone suffices to drive pancreatic neuroendocrine tumors, and to accelerate progression of KRAS-initiated precursor lesions to metastatic pancreatic ductal adenocarcinoma (PDAC). Our phenotype exposed suppression of the type I interferon (IFN) pathway by the combined actions of MYC and KRAS, and we present evidence of repressive MYC–MIZ1 complexes binding directly to the promoters of the genes encodiing the type I IFN regulators IRF5, IRF7, STAT1, and STAT2. Derepression of IFN regulator genes allows pancreatic tumor infiltration by B and natural killer (NK) cells, resulting in increased survival. Significance: We define herein a novel mechanism of evasion of NK cell–mediated immunity through the combined actions of endogenously expressed mutant KRAS and modestly deregulated expression of MYC, via suppression of the type I IFN pathway. Restoration of IFN signaling may improve outcomes for patients with PDAC. This article is highlighted in the In This Issue feature, p. 747
HALF DOSE VS FULL DOSE THROMBOLYSIS IN PROSTHETIC VALVE THROMBOSIS: IN QUEST OF A BETTER TREATMENT
Authors: Vikram Patil, Balaraj Doddaiah, Satvic Manjunath, Sushrit Neelopant, Lachikarathman Devegowda, Krishnan Shanmugam, Sridhar Sastry, Prabhavathi Bhat, Manjunath Cholenahalli Nanjappa
Journal: Journal of the American College of Cardiology (2020)
Abstract 16316: Difference in Heart Failure Readmission Time Trends Before and After Readmission Penalties in US Hospitals
Authors: Dinesh Kadariya, Rehan Qayyum
Journal: Circulation (2018)

Introduction: Readmission rates for heart failure (HF) in US hospitals declined after announcement of readmission penalty in 2011. However, the effect of penalties on individual hospital readmissio...
BETA-BLOCKERS AND ANGIOTENSIN CONVERSION ENZYME INHIBITORS FOR THE PREVENTION OF ANTHRACYCLINE-INDUCED CARDIOMYOPATHY: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Authors: Leonardo Mees Knijnik, Raul Montanez-Valverde, Eduardo Saul, Manuel Rivera Maza
Journal: Journal of the American College of Cardiology (2020)
ADOLESCENTS AND ADULTS WITH A FONTAN CIRCULATION HAVE IMPAIRED NEUROCOGNITIVE FUNCTION THAT IS ASSOCIATED WITH REDUCED BRAIN VOLUME
Authors: Charlotte Verrall, Adrian Schembri, Yves d'Udekem, Diana Zannino, Karin Du Plessis, Stuart Grieve, Joseph Y.M. Yang, Julian Ayer, Mark MacKay, David Winlaw, Rachel Cordina
Journal: Journal of the American College of Cardiology (2020)
Risk of pneumonitis with mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus.
Authors: Vishal Navnitray Ranpura, Shenhong Wu
Journal: Journal of Clinical Oncology (2013)

e13573 Background: Pneumonitis is associated with the use of mTOR inhibitors, everolimus and temsirolimus, which have been used widely in cancer therapeutics and clinical trials. Currently, the overall risk of pneumonits in patients treated with mTOR inhibitors has not been defined. We performed a systematic review and meta-analysis of published clinical trials to assess the risk of pneumonitis in cancer patients treated with mTOR inhibitors. Methods: Databases from PUBMED, the Web of Science, and abstracts presented at the American Society of Clinical Oncology conferences until May 2012 were searched to identify relevant studies. Eligible studies included prospective clinical trials in which patients received treatment with everolimus or temsirolimus as a single agent or in combination with other agents. Summary incidence, relative risk (RR), and 95% confidence interval (CI) were calculated employing a fixed- or random-effects model based upon the heterogeneity of the included studies. Results: A total of 2,303 patients with a variety of tumors from 18 studies (everolimus: 12, temsirolimus: 6) were included for the analysis. The overall incidences of all-grade and high-grade pneumonitis with mTOR inhibitors were 6.5% (95% CI: 3.7-11.1%) and 2.5% (95% CI 1.2-5.4%) respectively. The risk of all-grade pneumonitis did not vary significantly with tumor types (P=0.079), but vary significantly with their combination with other agents (P&lt;0.001). There was no significant difference between everolimus and temsirolimus in the incidence of all-grade (P=0.22) and high-grade (P=0.28) pneumonitis. In comparison with controls, mTOR inhibitors significantly increased the risk of all-grade (RR=5.2, 95% CI: 2.09-12.93, P&lt;0.001) but not high-grade pneumonits (RR=2.63, 95% CI: 0.66-10.40, P=0.41). Conclusions: The risk of pneumonitis is increased in cancer patients receiving mTOR inhibitors without significant difference between everolimus and temsirolimus.
Randomized clinical trial on accelerated hyperfractionated versus hypofractionated preoperative radiotherapy for rectal cancer: A report on perioperative complication rates.
Authors: Iwona Wzietek, Marcin Bialas, Mariusz Kryj, Andrzej Chmielarz, Maciej Widel, Adam Idasiak, Agnieszka Namysl-Kaletka, Ewa Stobiecka, Ewa Chmielik, Jerzy Wydmanski, Rafal Suwinski
Journal: Journal of Clinical Oncology (2013)

506 Background: The aim of the study is to verify hypothesis that accelerated hyperfractionated preoperative radiotherapy for rectal cancer (HART) may provide a favorable long-term tolerance compared to treatment given in higher fraction (fx) doses (HYPO). This report focuses on early outcomes of the study. Comparison of late tissue reactions, evaluation of QLQ and long-term outcome in both trial arms is the ultimate goal. Methods: Between 2005 and 2011, 238 patients (pts) with cT3-4 resectable adenocarcinoma of the rectum were enrolled, which represents app. 70% of an overall trial size. The pts were randomly assigned to HART (n=122) or HYPO (n=116). The pelvis was irradiated 2x/day to the total dose of 42 Gy in 1.5 Gy/fx over 18 days (HART). Patients in HYPO received 39 Gy in 3.0 Gy/fx over 17 days. Postoperative chemotherapy (PCT) was given to ypN+ pts. Results: The actuarial perioperative complication rate at 1 year after treatment was 24.4% vs. 33.4% for HART and HYPO resp. (RR=0.69, p=0.13). The crude rate of pts with any surgical complication during the follow-up (median of 3.1 year) was 32/122 (26.2%) vs. 36/116 (31.0%) for HART and HYPO resp. (p= 0.41). If the values were expr. In terms of number of events (some pts had more than one complication) the rates were 55 events per 122 pts (HART) vs. 63 events per 116 pts (HYPO). Anastomotic leakage appeared in 11/122 HART pts (9.0%) vs. 16/116 in HYPO (13.8%). Anterior resection was performed in 48.8 % vs. 44.1% for HART and HYPO resp. PCT was given to 46.1% of the pts in HART and 45.4% in HYPO. There were no significant differences in 3-year loco-regional control (RR=1.08, p=0.44) and overall survival (RR=0.97, p=0.72) between HART and HYPO, with actuarial rates (for both arms) of 85% and 73% resp. Neither the rate of complicatons, nor type of surgery were influenced by duration of the interval RT-surgery (median 11, Std±18 days) Conclusions: The perioperative complication rate observed had the propensity to favor HART over HYPO, but the differences did not reach the level of statistical significance. Longer follow-up and the analysis encompassing all of the pts enrolled is required to fully address the study endpoints.
NON-INVASIVE SEISMOCARDIOGRAPHY CAN ACCURATELY TRACK CHANGES IN PULMONARY ARTERY PRESSURES DURING VASODILATOR CHALLENGE AT THE TIME OF RIGHT HEART CATHETERIZATION
Authors: Md Mobashir Hasan Shandhi, Joanna Fan, J. Alex Heller, Mozziyar Etemadi, Omer Inan, Liviu Klein
Journal: Journal of the American College of Cardiology (2020)